Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals (7/24/2023)
ESSEX, CT – (July 24, 2023) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a small molecule ChemR23 agonist to treat cancer and chronic inflammatory diseases, announced the appointment today of Joyce Steinberg, MD, FACP, as interim Chief Medical Officer.
Gary Mathias, Chief Executive Officer of Thetis, commented, “Dr Steinberg is a board-certified medical oncologist with over 20 years of biopharma industry experience at Astellas, Abbott, NeoPharm, Searle, and Fujisawa where she specialized in the development of small molecule and biologic therapies. Her experience in designing and overseeing clinical trials will be key as Thetis advances into clinical development of TP-317 for solid tumor cancers and IBD.”
About TP-317
Overview: TP-317 is a patented small molecule drug that delivers RvE1, an endogenous lipid mediator that regulates immune homeostasis. Unlike anti-inflammatory drugs and anti-cancer agents that are immuno-suppressive, TP-317 activates innate and adaptive immune pathways to treat disease without compromising host-protective immunity.
Cancer Program: In cancer, TP-317 is being developed as an adjunct to standard of care therapy in refractory metastatic melanoma, advanced non-small-cell lung cancer (NSCLC), and pancreatic cancer. Preclinical studies with oral TP-317 in tumor models of these cancers have shown potent single-agent activity, and enhanced efficacy when combined with immune checkpoint inhibitors or chemotherapy.
IBD Program: In IBD, TP-317 is being developed as first-line, oral therapy for mild-to-moderate Crohn’s disease and as second-line, oral therapy for mild-to-moderate ulcerative colitis in patients who are not well controlled on 5-ASA or corticosteroids. TP-317 also has potential to treat moderate-to-severe IBD as adjunct therapy to standard-of-care biologics or oral immunomodulators. The anticipated high safety premium for TP-317 further supports early intervention in IBD and other immune disorders.
About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and inflammatory bowel disease. Thetis’ proprietary HEALER™ technology enables the pharmaceutical development of Resolvins, overcoming the stability, manufacturing, and formulation hurdles that have limited their commercial development. Thetis is supported by venture capital investors, NIH, and leading private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.
Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.
Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com.